NUVB Nuvation Bio Inc.
Company Analysis
Latest News
🔴 Nuvation Bio is trading 4% down today in a pullback after recent gains
Nuvation Bio is trading at $6.42 (4% down) in early trading, appearing to pull back after recent gains despite a lack of fresh company-specific catalysts. •...
🟢 Nuvation Bio rises 4.6% — Biotech Sector Rallies on Blockbuster M&A Deal and Positive Trial Data
With Biotech (XBI) up 2.3%, this looks like a sector-led move rather than a company-specific surprise. The biotechnology sector is experiencing a significant...
🔴 Nuvation Bio is trading 5.1% down
Nuvation Bio is trading at $6.11, down 5.1% from a comparison close of $6.43 during regular trading. This is a price-action follow-up, so a separate catalyst...
🟢 Nuvation Bio is trading 4.7% up today on positive Phase 2 data for brain tumor drug safusidenib
Nuvation Bio is trading 4.7% up today at $6.55 following the release of positive updated Phase 2 data for its brain tumor drug, safusidenib. • The company...
Nuvation Bio Advances Brain Tumor Drug, Citing 79% Progression-Free Survival
Nuvation Bio reported positive long-term Phase 2 data for safusidenib in patients with IDH1-mutant glioma. The trial reached nearly 40 months of...
🟢 Nuvation Bio is trading 10.8% up
Nuvation Bio is trading at $6.42, up 10.8% from a comparison close of $5.80 during regular trading. This is a price-action follow-up, so a separate catalyst...
Nuvation Bio Advances Safusidenib to Phase 3, Aiming to Delay Chemotherapy
Nuvation Bio initiated a pivotal Phase 3 clinical trial for its targeted cancer therapy, safusidenib. The study focuses on patients with Grade 2 glioma...
🔴 Nuvation Bio is trading 4.2% down today amidst ongoing investor concerns following its $287.5M convertible notes offering
Nuvation Bio is trading at $5.66 (4.2% down) with investors continuing to react to its recently completed $287.5 million convertible senior notes offering. •...
🟢 Nuvation Bio is trading 4.3% up today with no clear company-specific catalyst
Nuvation Bio is trading at $6.02 (+4.33%) with no clear company-specific catalyst identified to drive the upward move during the July 14, 2026 session. • The...
🔴 Nuvation Bio is trading 4.01% down today in a pullback after a prior-day rebound
Nuvation Bio is trading at $5.87 (-4.01%) in an apparent pullback following the prior session’s 4.09% gain and a recent multi-day rebound. • No...
🟢 Nuvation Bio Surges as UK Regulators Validate Taletrectinib Application
Nuvation Bio is trading at $6.12 (up 4.3%), extending its multi-day rebound. The surge follows: * The UK Medicines and Healthcare products Regulatory Agency...
Nuvation Bio Completes $287.5M Convertible Note Offering After Full Greenshoe Exercise
Nuvation Bio Inc. announced that the underwriters for its recent convertible senior notes offering fully exercised their over-allotment option. This exercise...
🔴 NUVB is trading 5% down today as investors digest an upsized $250M convertible notes offering
NUVB is trading at $5.39 (5% down) as the market continues to react to the company's recent $250 million 0.75% convertible senior notes offering due 2032. •...
Nuvation Bio Completes $250 Million Convertible Senior Notes Offering Due 2032
Nuvation Bio Inc. has completed its registered public offering of $250.0 million in aggregate principal amount of 0.75% Convertible Senior Notes maturing on...
🟢 NUVB is trading 5.3% up today after announcing an upsized $250M convertible notes offering
NUVB is trading 5.3% up at $5.91 after announcing an upsized $250 million convertible senior notes offering. • The sale is expected to close on June 30, 2026,...
Nuvation Bio Enters UK Review for Lung Cancer Drug, MHRA Validates Application
Nuvation Bio’s lung cancer drug, taletrectinib, has entered the formal review process in the United Kingdom. The Medicines and Healthcare products Regulatory...
🔴 NUVB is trading 5.1% down today after upsizing its convertible notes offering to $250 million
NUVB is trading at $5.51 (5.1% down) after the company increased its planned convertible notes sale to $250 million. • The upsized offering of 0.75%...
Nuvation Bio Raises $200 Million in Convertible Debt — But Why Now, With Half a Billion Already in the Bank?
Shares of Nuvation Bio (NUVB) tumbled 11.8% to $5.70 on June 25 after the oncology company announced a $200 million convertible senior notes offering due 2032,...
🔴 NUVB is trading 11.8% down today after $200M convertible senior notes offering
NUVB is trading 11.8% down at $5.70 following the announcement of a $200 million convertible senior notes offering due in 2032. • The financing news has...
🔴 NUVB plunges 14.9% after announcing $200M convertible senior notes offering
• NUVB is trading at $5.50 (14.9% down) in pre-market action today. • The decline follows the company's announcement of a proposed $200.0 million Convertible...